BIOMAT Database Logo BIOMAT Database Logo

Development and evaluation of a national reference panel of HIV-1 protease and reverse transcriptase drug-resistance mutations for HIV-1 genotypic resistance assays in China. 2010

Sihong Xu, and Jingyun Li, and Zuoyi Bao, and Hui Xing, and Ping Zhong, and Hanping Li, and Haiwei Zhou, and Xinping Li, and Sharon Wu, and Aijing Song, and Xiuhua Li, and Jianhui Nie, and Youchun Wang
Department of Cell Biology, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, China.

BACKGROUND Transmission of antiretroviral drug-resistant strains of HIV-1 has a major impact on the success of HIV treatment regimens in most countries where antiretroviral therapy (ART) is available. It is now recommended that HIV-1 drug resistance be monitored in order to recommend appropriate therapy for infected ART-naïve individuals, or when choosing a new regimen for those patients not responding to ART. Commercial assays for the analysis of HIV-1 genotypic resistance have been approved by the US FDA. In China, several laboratories and research enterprises have been developing related assays, but at present, no systematic standardization or quality control for genotypic resistance assays has been established in China. A national reference panel is needed to evaluate and control the quality of HIV-1 genotype resistance assays in China. METHODS A panel of five HIV-1 stocks (G1, G2, G3, G4, and G5) with well-characterized drug resistance was used to evaluate the resistance-mutation inclusivity of HIV-1 clades prevalent in China. Six samples (GS1-GS6) were used to evaluate the limit of detection (LOD) for the viral load levels, and five samples (GSS1-GSS3, GSS5, and GSS6) were used to evaluate the LOD for the percentages of mutant species within the range of detection. The samples were evaluated by five separate laboratories using one or two methods each, generating seven datasets in all. RESULTS In samples G1-G5, which were used to evaluate inclusivity of HIV-1 clades, 92.86-100%, 16.67-83.33% and 4.17-8.33% of the most, intermediately, and least common resistance mutations, respectively, were reported by the seven datasets. For the LOD samples, four of the seven datasets reported correct resistance mutations in samples with minimal viral loads of >2 x 10(3) copies/mL, as well as in samples with >40% of mutants and viral loads of about 1 x 10(4) copies/mL; the other three tests did not amplify the target region or identify the mutants. CONCLUSIONS The results were quite variable between different tests. The panel of HIV-1 genotypic resistance could be used as a control for resistance testing in China.

UI MeSH Term Description Entries
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077552 Basiliximab A chimeric murine-human monoclonal antibody that functions as an INTERLEUKIN 2 RECEPTOR antagonist by binding to the alpha chain (CD25 ANTIGEN) of the interleukin-2 receptor on the surface of activated T-LYMPHOCYTES. It is used in the prevention of acute graft rejection episodes in patients undergoing renal transplantation. CHI 621,SDZ CHI 621,Simulect
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016333 HIV Protease Enzyme of the human immunodeficiency virus that is required for post-translational cleavage of gag and gag-pol precursor polyproteins into functional products needed for viral assembly. HIV protease is an aspartic protease encoded by the amino terminus of the pol gene. HIV Proteinase,HTLV-III Protease,p16 pol gene product, HIV,p16 protease, HIV,HIV p16 protease,HTLV III Protease,Protease, HIV,Protease, HTLV-III
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D057230 Limit of Detection Concentration or quantity that is derived from the smallest measure that can be detected with reasonable certainty for a given analytical procedure. Limits of Detection,Detection Limit,Detection Limits

Related Publications

Sihong Xu, and Jingyun Li, and Zuoyi Bao, and Hui Xing, and Ping Zhong, and Hanping Li, and Haiwei Zhou, and Xinping Li, and Sharon Wu, and Aijing Song, and Xiuhua Li, and Jianhui Nie, and Youchun Wang
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.
January 2007, AIDS (London, England),
Sihong Xu, and Jingyun Li, and Zuoyi Bao, and Hui Xing, and Ping Zhong, and Hanping Li, and Haiwei Zhou, and Xinping Li, and Sharon Wu, and Aijing Song, and Xiuhua Li, and Jianhui Nie, and Youchun Wang
HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms.
May 2003, Journal of acquired immune deficiency syndromes (1999),
Sihong Xu, and Jingyun Li, and Zuoyi Bao, and Hui Xing, and Ping Zhong, and Hanping Li, and Haiwei Zhou, and Xinping Li, and Sharon Wu, and Aijing Song, and Xiuhua Li, and Jianhui Nie, and Youchun Wang
Genotypic analysis methods for detection of drug resistance mutations in the HIV-1 proteinase and reverse transcriptase genes.
January 1999, Antiviral therapy,
Sihong Xu, and Jingyun Li, and Zuoyi Bao, and Hui Xing, and Ping Zhong, and Hanping Li, and Haiwei Zhou, and Xinping Li, and Sharon Wu, and Aijing Song, and Xiuhua Li, and Jianhui Nie, and Youchun Wang
HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naïve HIV-infected individuals.
January 2020, PloS one,
Sihong Xu, and Jingyun Li, and Zuoyi Bao, and Hui Xing, and Ping Zhong, and Hanping Li, and Haiwei Zhou, and Xinping Li, and Sharon Wu, and Aijing Song, and Xiuhua Li, and Jianhui Nie, and Youchun Wang
A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.
January 2001, HIV sequence compendium,
Sihong Xu, and Jingyun Li, and Zuoyi Bao, and Hui Xing, and Ping Zhong, and Hanping Li, and Haiwei Zhou, and Xinping Li, and Sharon Wu, and Aijing Song, and Xiuhua Li, and Jianhui Nie, and Youchun Wang
Frequency of protease and reverse transcriptase drug resistance mutations in naïve HIV-infected patients.
November 2006, Archives of medical research,
Sihong Xu, and Jingyun Li, and Zuoyi Bao, and Hui Xing, and Ping Zhong, and Hanping Li, and Haiwei Zhou, and Xinping Li, and Sharon Wu, and Aijing Song, and Xiuhua Li, and Jianhui Nie, and Youchun Wang
Fast genotypic detection of drug resistance mutations in the HIV-1 reverse transcriptase gene of treatment-naive patients.
January 1998, Journal of human virology,
Sihong Xu, and Jingyun Li, and Zuoyi Bao, and Hui Xing, and Ping Zhong, and Hanping Li, and Haiwei Zhou, and Xinping Li, and Sharon Wu, and Aijing Song, and Xiuhua Li, and Jianhui Nie, and Youchun Wang
HIV-1 viral load and phenotypic antiretroviral drug resistance assays based on reverse transcriptase activity in comparison to amplification based HIV-1 RNA and genotypic assays.
January 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
Sihong Xu, and Jingyun Li, and Zuoyi Bao, and Hui Xing, and Ping Zhong, and Hanping Li, and Haiwei Zhou, and Xinping Li, and Sharon Wu, and Aijing Song, and Xiuhua Li, and Jianhui Nie, and Youchun Wang
Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase.
February 2008, AIDS (London, England),
Sihong Xu, and Jingyun Li, and Zuoyi Bao, and Hui Xing, and Ping Zhong, and Hanping Li, and Haiwei Zhou, and Xinping Li, and Sharon Wu, and Aijing Song, and Xiuhua Li, and Jianhui Nie, and Youchun Wang
Development of a new comprehensive HIV-1 genotypic drug resistance assay for all commercially available reverse transcriptase, protease and integrase inhibitors in patients infected with group M HIV-1 strains.
July 2020, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases,
Copied contents to your clipboard!